Molecular Partners Ag Stock Price on November 25, 2024
| MOLN Stock | USD 5.29 0.13 2.40% |
If you're considering investing in Molecular Stock, it is important to understand the factors that can impact its price. As of today, the current price of Molecular Partners stands at 5.29, as last reported on the 25th of November, with the highest price reaching 5.29 and the lowest price hitting 5.29 during the day. Molecular Partners has Sharpe Ratio of -0.025, which conveys that the firm had a -0.025% return per unit of risk over the last 3 months. Molecular Partners exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Molecular Partners' insignificant Risk Adjusted Performance, mean deviation of 4.66, and Standard Deviation of 7.36 to check out the risk estimate we provide.
As of the 25th of November 2024, Stock Based Compensation To Revenue is likely to grow to 0.78, while Total Stockholder Equity is likely to drop about 137.3 M. . At this time, Molecular Partners' Price To Sales Ratio is very stable compared to the past year. As of the 25th of November 2024, Price Sales Ratio is likely to grow to 20.88, while Price Earnings Ratio is likely to drop (1.91). Molecular Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
Molecular |
Sharpe Ratio = -0.025
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MOLN |
Estimated Market Risk
| 7.27 actual daily | 64 64% of assets are less volatile |
Expected Return
| -0.18 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Molecular Partners is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Molecular Partners by adding Molecular Partners to a well-diversified portfolio.
Price Book 1.2444 | Enterprise Value Ebitda 1.2347 | Price Sales 33.5585 | Shares Float 6.5 M | Wall Street Target Price 9.331 |
Molecular Partners Valuation on November 25, 2024
It is possible to determine the worth of Molecular Partners on a given historical date. On November 25, 2024 Molecular was worth 5.29 at the beginning of the trading date compared to the closed value of 5.29. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Molecular Partners stock. Still, in general, we apply an absolute valuation method to find Molecular Partners' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Molecular Partners where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Molecular Partners' related companies.
| Open | High | Low | Close | Volume | |
| 5.29 | 5.29 | 5.29 | 5.29 | 785.00 | |
11/25/2024 | 5.29 | 5.29 | 5.29 | 5.29 | 0.00 |
| Backtest Molecular Partners | | | Molecular Partners History | | | Molecular Partners Valuation | Previous |
Molecular Partners Trading Date Momentum on November 25, 2024
| On November 25 2024 Molecular Partners AG was traded for 5.29 at the closing time. The top price for the day was 5.29 and the lowest listed price was 5.29 . There was no trading activity during the period 0.0. Lack of trading volume on November 25, 2024 did not cause price change. The trading delta at closing time against the current closing price is 0.00% . |
Molecular Partners Fundamentals Correlations and Trends
By evaluating Molecular Partners' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Molecular Partners' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Molecular financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Molecular Partners Stock history
Molecular Partners investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Molecular is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Molecular Partners will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Molecular Partners stock prices may prove useful in developing a viable investing in Molecular Partners
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 32.8 M | 26 M | |
| Net Income Applicable To Common Shares | 135.5 M | 142.3 M |
Molecular Partners Quarterly Net Working Capital |
|
Molecular Partners Stock Technical Analysis
Molecular Partners technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Molecular Partners Period Price Range
Low | November 25, 2024
| High |
0.00 | 0.00 |
Molecular Partners AG cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Molecular Partners November 25, 2024 Market Strength
Market strength indicators help investors to evaluate how Molecular Partners stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Molecular Partners shares will generate the highest return on investment. By undertsting and applying Molecular Partners stock market strength indicators, traders can identify Molecular Partners AG entry and exit signals to maximize returns
Molecular Partners Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Molecular Partners' price direction in advance. Along with the technical and fundamental analysis of Molecular Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Molecular to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0) | |||
| Jensen Alpha | (0.26) | |||
| Total Risk Alpha | (1.28) | |||
| Treynor Ratio | (0.11) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.13) | Revenue Per Share 0.182 | Quarterly Revenue Growth (0.73) | Return On Assets (0.21) | Return On Equity (0.37) |
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.